(Q33412367)

26 July 2017

title

The pros and the cons of mTOR inhibitors in kidney transplantation (English)

1 reference

26 July 2017

main subject

kidney transplantation

1 reference

Claudio Ponticelli

1

1 reference

26 July 2017

publication date

30 December 2013

1 reference

Expert Review of Clinical Immunology

26 July 2017

published in

1 reference

26 July 2017

volume

10

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

295-305

1 reference

Dissecting the role of mTOR: lessons from mTOR inhibitors

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

The mechanisms of acute transplant rejection revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Open new possibilities in Transplantation Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Autophagy in atherosclerosis: a potential drug target for plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Posttransplant anemia: the role of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

mTOR inhibition and erythropoiesis: microcytosis or anaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Lymphocele after renal transplantation, a medical complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus (Rapamune) in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sympathetic dystrophy associated with sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-α activation and disruption of the p120-vascular endothelial cadherin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Proteinuria after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

mTOR inhibitor-associated proteinuria in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Factors associated with proteinuria in renal transplant recipients treated with sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus interacts with pathways essential for podocyte integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.872562

10.1586/1744666X.2014.872562

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference